Chromosomal rearrangements involving the ABL1 gene, leading to a BCR‐ABL1 fusion
gene, have been mainly associated with chronic myeloid leukemia and B‐cell acute …

Cytoreductive surgery and empirical combination chemotherapy have improved 5-year
survival for ovarian cancer patients, but have not increased the overall rate of cure. Poor …

In recent years, structural and functional studies reveal that tyrosine kinases (TKs) act as the
essential components of signal transduction pathways that regulate cancer cell proliferation …

Leukemias expressing the constitutively activated tyrosine kinases (TK) BCR-ABL1 and
FLT3/ITD activate signaling pathways that increase genomic instability through generation of …

Dasatinib is a second-generation tyrosine kinase inhibitor (TKI) for chronic, blastic, or
accelerated phase chronic myeloid leukemia (CML) patients who are resistant or intolerant …

Background The purpose of the study was to assess renal function in patients with
Philadelphia chromosome-positive leukemias receiving bosutinib or imatinib. Patients and …

BACKGROUND Tyrosine kinase inhibitors (TKIs) improve the survival of patients with
chronic myeloid leukemia (CML) dramatically; however, nonadherence to TKI therapy may …

Increased numbers of immunosuppressive myeloid derived suppressor cells (MDSCs)
correlate with a poor prognosis in cancer patients. Tyrosine kinase inhibitors (TKIs) are used …

Imatinib mesylate (IM) has become a standard of care in chronic myeloid leukemia (CML)
therapy. Single nucleotide polymorphisms (SNPs) and altered expression in drug …

Ponatinib, the only approved all known-BCR:: ABL1 inhibitor, is a third-generation tyrosine-
kinase inhibitor (TKI) designed to inhibit BCR:: ABL1 with or without any single resistance …